FDA Approves Gilead’s Bixlenvo for HIV Treatment

Foster City, California, August 27, 2026

Bixlenvo Offers a Once-Daily Single-Tablet Regimen

The FDA approval covers adults who are virologically suppressed, defined as having HIV-1 RNA levels below 50 copies/mL, and who are stable on their current antiretroviral regimen. Patients must have no known or suspected resistance to the individual components of Bixlenvo. The regimen is intended to replace an existing antiretroviral treatment rather than serve as initial HIV therapy, making the approval particularly relevant to people whose current treatment involves multiple tablets or more frequent daily dosing. Bixlenvo contains two antiretroviral medicines that target HIV through different mechanisms. Bictegravir inhibits HIV integrase, an enzyme required for viral DNA integration into the host genome, while lenacapavir targets the HIV capsid. Gilead developed the combination as a simplified oral option for virologically suppressed adults whose treatment needs may make currently available single-tablet regimens unsuitable. The company describes Bixlenvo as the smallest single-tablet regimen and the first single-tablet regimen specifically indicated for this population.

Phase 3 ARTISTRY Studies Support Approval

The FDA decision was supported by results from the Phase 3 ARTISTRY-1 and ARTISTRY-2 clinical trials, which evaluated Bixlenvo in adults with HIV who were already virologically suppressed. The studies assessed whether participants could maintain virologic suppression after switching from their existing antiretroviral therapy to Bixlenvo. Across the clinical program, the investigational regimen demonstrated comparable maintenance of virologic suppression at Week 48 and was generally well tolerated. ARTISTRY-1 evaluated a highly treatment-experienced population. Participants had a median age of approximately 60 years and had received HIV treatment for a median of about 28 years. At study entry, participants were taking between two and 11 pills per day, while a substantial proportion were receiving antiretroviral therapy more than once daily. Historical antiretroviral resistance was also common, highlighting the complexity of treatment in the population studied. ARTISTRY-2 evaluated adults switching to Bixlenvo from Biktarvy®, another Gilead HIV treatment. Results supported maintenance of virologic suppression following the treatment switch. The clinical findings across the ARTISTRY program provided the evidence supporting Bixlenvo’s FDA approval for virologically suppressed adults meeting the specified treatment criteria.

Dosing and Safety Considerations

Although Bixlenvo is ultimately administered as a once-daily tablet, treatment begins with a two-day initiation regimen involving Sunlenca® (lenacapavir). On Days 1 and 2, patients take one Bixlenvo tablet together with two Sunlenca tablets, followed by one Bixlenvo tablet once daily beginning on Day 3. This dosing schedule is part of the FDA-approved regimen. The prescribing information includes important drug-interaction and safety considerations. Bixlenvo is contraindicated with dofetilide and strong CYP3A inducers, which can affect drug concentrations and potentially compromise treatment or increase safety risks. Healthcare professionals should therefore review concomitant medications before initiating treatment. The most commonly reported adverse reactions in the clinical studies included headache, nausea and diarrhea. The product information also addresses considerations relating to pregnancy, lactation and monitoring of viral load during pregnancy. As with other antiretroviral therapies, continued clinical monitoring is important to support treatment effectiveness and patient safety. The FDA approval of Bixlenvo expands the therapeutic options available to virologically suppressed adults living with HIV, particularly those managing complex treatment regimens. By combining bictegravir and lenacapavir in a single daily tablet, the regimen is designed to reduce pill burden while maintaining viral suppression in an experienced HIV-treatment population. The approval represents another development in HIV medicine focused on treatment simplification and individualized long-term care.

Source: Gilead Sciences press relese